See more : Rama Petrochemicals Limited (RAMAPETRO.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Incannex Healthcare Limited (IXHL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Incannex Healthcare Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- PC Depot Corporation (7618.T) Income Statement Analysis – Financial Results
- Valuence Merger Corp. I (VMCAU) Income Statement Analysis – Financial Results
- Culp, Inc. (CULP) Income Statement Analysis – Financial Results
- WSM for Information Technology Co. (9595.SR) Income Statement Analysis – Financial Results
- Hidong Estate Plc (HID.L) Income Statement Analysis – Financial Results
Incannex Healthcare Limited (IXHL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.incannex.com.au
About Incannex Healthcare Limited
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.00K | 0.00 | 540.17K | 1.42M | 417.45K | 1.09K | 749.19K | 216.77K | 68.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 4.38K | 683.84K | 310.80K | 0.00 | 387.89K | 396.97K | 48.92K | 13.76K | 430.76K | 757.99K | 1.22M | 41.75K | 391.02K | 0.00 | 0.00 | 0.00 | 15.29K |
| Gross Profit | 12.00K | 0.00 | 535.79K | 739.07K | 106.65K | 1.09K | 361.30K | -180.20K | 19.38K | -13.76K | -430.76K | -757.99K | -1.22M | -41.75K | -391.02K | 0.00 | 0.00 | 0.00 | -15.29K |
| Gross Profit Ratio | 100.00% | 0.00% | 99.19% | 51.94% | 25.55% | 100.00% | 48.23% | -83.13% | 28.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.88M | 41.66M | 3.71M | 3.54M | 1.46M | 516.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 16.83M | 7.93M | 193.99K | 74.31K | 315.85K | 231.80K | 573.43K | 612.04K | 268.89K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 348.00K | 84.00K | 1.90M | 3.26M | 280.35K | 66.56K | 901.40K | 423.04K | 53.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.17M | 8.01M | 4.66M | 4.84M | 1.35M | 375.15K | 2.58M | 1.85M | 509.60K | 486.81K | 397.05K | 1.37M | 1.15M | 2.73M | 361.62K | 513.85K | 826.11K | 839.29K | 107.68K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.49K | -93.16K | -202.43K | -152.02K | -180.81K | 0.00 | -131.67K | -27.52K | -24.19K |
| Operating Expenses | 30.05M | 49.67M | 8.37M | 8.40M | 2.81M | 891.96K | 2.58M | 1.85M | 509.60K | 486.81K | 390.56K | 1.46M | 1.35M | 2.88M | 180.81K | 513.85K | 957.78K | 866.81K | 131.87K |
| Cost & Expenses | 30.05M | 49.67M | 8.38M | 9.09M | 3.12M | 891.96K | 2.97M | 2.24M | 558.53K | -500.57K | -821.32K | -2.22M | -2.57M | -2.92M | -571.82K | -639.67K | -999.62K | -875.38K | -147.16K |
| Interest Income | 206.00K | 244.01K | 4.55K | 2.00K | 3.05K | 1.11K | 2.36K | 6.53K | 424.25 | 3.18K | 16.34K | 122.80K | 126.22K | 99.59K | 32.62K | 6.91K | 224.50K | 44.01K | 1.18K |
| Interest Expense | 0.00 | 3.01K | 218.07 | -10.46 | -89.80 | 60.83K | 9.98K | 37.56K | 89.76 | 99.84K | 160.04K | 195.54K | 194.91K | 93.67K | 107.56K | 35.09K | 10.92K | 5.05K | 15.59K |
| Depreciation & Amortization | 103.00K | 23.00K | 7.84M | 7.64M | 28.91K | 29.95K | 42.33K | 23.27K | 11.93K | 13.76K | 36.25K | 29.41K | 42.58K | 41.75K | 45.15K | 41.29K | 41.84K | 8.56K | 340.77 |
| EBITDA | -18.50M | -13.62M | 0.00 | 0.00 | -2.59M | -861.46K | -2.22M | -2.03M | -490.22K | -2.09M | -12.10M | -13.22M | -3.27M | -4.43M | 2.38M | -2.79M | -932.05K | -820.09K | -163.01K |
| EBITDA Ratio | -154,200.00% | 0.00% | 0.00% | 0.00% | -619.34% | -79,012.56% | -295.87% | -935.19% | -717.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -30.04M | -49.67M | -7.84M | -7.66M | -2.70M | -890.87K | -2.22M | -2.03M | -490.22K | -500.57K | -821.32K | -2.22M | -2.57M | -2.92M | -571.82K | -639.67K | -999.62K | -875.38K | -147.16K |
| Operating Income Ratio | -250,341.67% | 0.00% | -1,450.78% | -538.64% | -646.62% | -81,709.63% | -295.87% | -935.19% | -717.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.61M | 857.00K | -2.45M | -863.45K | -12.42K | -110.40K | -160.17K | -14.11M | -59.59K | -1.70M | -11.48M | -11.23M | -936.03K | -1.64M | 2.80M | -2.23M | 14.81K | 41.67K | -31.78K |
| Income Before Tax | -18.43M | -48.81M | -10.29M | -8.53M | -2.71M | -1.00M | -2.38M | -16.14M | -549.82K | -2.20M | -12.30M | -13.45M | -3.51M | -4.56M | 2.23M | -2.87M | -984.81K | -833.71K | -178.94K |
| Income Before Tax Ratio | -153,575.00% | 0.00% | -1,904.94% | -599.33% | -649.59% | -91,835.01% | -317.25% | -7,444.24% | -804.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -204.00K | -229.80K | 0.00 | -88.06K | -1.32M | -1.09M | -278.89K | 0.00 | 0.00 | -18.10K | 0.00 | 0.00 | 0.00 |
| Net Income | -18.46M | -48.81M | -10.29M | -8.53M | -3.24M | -1.91M | -2.18M | -15.90M | -549.82K | -2.11M | -10.98M | -12.36M | -3.23M | -4.56M | 2.23M | -2.85M | -984.81K | -833.71K | -178.94K |
| Net Income Ratio | -153,825.00% | 0.00% | -1,904.94% | -599.33% | -776.62% | -175,041.70% | -291.24% | -7,336.20% | -804.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.14 | -3.17 | -0.03 | -0.03 | -0.02 | -0.01 | -0.04 | -0.50 | -0.04 | -0.17 | -1.08 | -1.34 | -0.50 | -1.07 | 0.90 | -1.72 | -0.73 | -1.18 | -0.37 |
| EPS Diluted | -1.14 | -3.17 | -0.03 | -0.03 | -0.02 | -0.01 | -0.04 | -0.50 | -0.04 | -0.17 | -1.08 | -1.34 | -0.50 | -0.73 | 0.51 | -1.72 | -0.73 | -1.13 | -0.37 |
| Weighted Avg Shares Out | 16.16M | 15.38M | 297.79M | 244.23M | 171.01M | 111.86M | 57.00M | 31.91M | 15.69M | 12.11M | 10.20M | 9.21M | 6.50M | 4.05M | 2.47M | 1.65M | 1.35M | 706.01K | 481.06K |
| Weighted Avg Shares Out (Dil) | 16.16M | 15.38M | 297.79M | 244.23M | 171.01M | 111.86M | 57.00M | 31.91M | 15.69M | 12.11M | 10.20M | 9.21M | 6.50M | 5.88M | 4.37M | 1.65M | 1.35M | 738.99K | 481.06K |
Incannex Healthcare Announces Completion of its Redomiciliation to the United States
MELBOURNE, Australia and NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ: IXHL) is pleased to announce that its previously announced transaction to redomicile Incannex Healthcare from Australia to the United States has been implemented as of...
Federal Court of Australia Approves Incannex's Re-Domiciliation and Lodgement of Court Orders With ASIC
MELBOURNE, Australia, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) (the “Company” or “Incannex”) is pleased to announce that the Federal Court of Australia (“Court”) has today made orders approving the scheme of arrangement in...
Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023
MELBOURNE, Australia, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a pharmaceutical company developing cannabinoid pharmaceutical medicines and psychedelic therapies for unmet medical needs, is pleased to announce that it will...
Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD
MELBOURNE, Australia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to...
Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed
MELBOURNE, Australia, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs, is pleased to announce that...
Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening
Highlights: Incannex subsidiary, Clarion Clinics Group Pty Ltd (Clarion) begins accepting registrations of interest in its psychedelic-assisted therapy (PAT) treatments ahead of planned Q3 opening. First clinic in Abbotsford, Melbourne, nearing fit-out completion.
Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), (‘Incannex' or the ‘Company'), is pleased to provide its quarterly activities report and appendix 4C for the period ended 30...
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis
MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to...
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea
MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to...
Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea
Highlights: Incannex has engaged Fortrea as the contract research organisation (‘CRO') to manage the IND opening Phase 2/3 clinical trial investigating IHL-42X for treatment of OSA. The Phase 2/3 clinical trial will assess the safety and efficacy of IHL-42X in...
Source: https://incomestatements.info
Category: Stock Reports